Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dalpiciclib + AI vs Chemotherapy in Neoadjuvant ER+ HER2- Breast Cancer
NCT06107673Phase 2Recruiting
- Sponsor
- The Fourth Hospital of Hebei Medical University
- Start
- Sep 2023
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of dalpiciclib in breast cancer, sponsored by The Fourth Hospital of Hebei Medical University. Started Sep 2023; status: recruiting.
02
Drugs
dalpiciclib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT06107673.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06107673.